Telix Pharmaceuticals Limited
Every calculator, already run for TLX
Open the full toolkit →You have the numbers on TLX. Get the argument.
A written report on which of these readings actually decide the outcome for Telix Pharmaceuticals Limited, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
5 analysts covering TLXAnalyst Price Target Disagreement for Telix Pharmaceuticals Limited
Wall Street's bull case implies +90% from the current price; the bear case implies +72%. Analysts are relatively aligned on TLX's range.
Ownership & short interest
Insider Trading Activity for TLX
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem c…
TLX — frequently asked
Is TLX a buy right now?
Wall Street's consensus rating on Telix Pharmaceuticals Limited is Strong Buy across 5 analysts, with a mean price target of $21.19 (+82% vs. the current $11.66). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is TLX overvalued?
TLX trades at 116.6x trailing earnings. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
What is the analyst price target disagreement for Telix Pharmaceuticals Limited?
Analysts covering Telix Pharmaceuticals Limited (TLX) range from a bear-case target of $20.00 to a bull-case high of $22.13, with a mean consensus target of $21.19 across 4 analysts. The spread of $2.13 (18% of the current price) indicates moderate disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Telix Pharmaceuticals Limited against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Telix Pharmaceuticals Limited
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full TLX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Telix Pharmaceuticals Limited, in minutes. 3 free reports included with every account — no credit card required.